Latest Breaking News On - Seiichi sato - Page 1 : comparemela.com

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAmanda sheldonSeiichi satoDerek coleFrank watanabeSato pharmaceutical co ltdExchange commissionArcutis biotherapeutics incInvestor relations advisory solutionsHead of corporate communicationsGreater chinaPrescribing informationSato pharmaceuticalPrivate securities litigation reform actRelations advisory

Arcutis Biotherapeutics (ARQT) and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Arcutis Biotherapeutics (ARQT) and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrank watanabeSeiichi satoArcutis biotherapeutics incSato pharmaceutical co ltdGreater china

Arcutis And Sato Announce Strategic Collaboration And Licensing Agreement For Topical Roflumilast In Japan

Arcutis And Sato Announce Strategic Collaboration And Licensing Agreement For Topical Roflumilast In Japan
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesAmanda sheldonArcutis satoSeiichi satoFrank watanabeHead of corporate communicationsExchange commissionArcutis biotherapeutics incSato pharmaceutical co ltdGreater chinaSoutheast asiaPrescribing informationSato pharmaceuticalPrivate securities litigation reform act

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone payments (totaling $40 million), as well as tiered, double-digit royaltiesAgreement offers pathway to potentially offering a novel non-steroidal topical option to the millions of Japanese patients suffering from inflammatory skin diseases WESTLAKE VILLAGE, Calif. and TOKYO, Feb. 28, 2024 (GLOBE NEWSWIRE) Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage bi

United statesFrank watanabeAmanda sheldonSeiichi satoHead of corporate communicationsSato pharmaceutical co ltdExchange commissionArcutis biotherapeutics incGreater chinaPrescribing informationSato pharmaceuticalPrivate securities litigation reform act

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone payments (totaling $40.

United statesFrank watanabeSeiichi satoAmanda sheldonDerek coleExchange commissionSato pharmaceutical co ltdInvestor relations advisory solutionsHead of corporate communicationsArcutis biotherapeutics incGreater chinaPrescribing informationSato pharmaceuticalPrivate securities litigation reform act